Is a PET/MRI scan better than a PET/CT scan at visualising bone lesions and their change with treatment in adults with myeloma?

Response evaluation in myeloma patients using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN15606951

Enrollment

Registered

2020-02-12

Start date

2017-01-04

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloma Cancer

Interventions

Participants will be identified, screened and approached. Participants will be consented by the clinical team, research team or appropriately trained delegates. PET/CT and PET/MR appointments will be

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Newly diagnosed with myeloma

Exclusion criteria

Exclusion criteria: 1. Contraindication to PET/CT or PET/MR 2. Unable to provide informed consent.

Design outcomes

Primary

Measure	Time frame
1. Myeloma bone disease detection, calculated using using focal lesion number, MRI bone marrow pattern and functional parameters including SUVmax, ADC and fat fraction parameters, assessed by PET/CT and PET/MRI at baseline and at 4-6 weeks following completion of induction chemotherapy 2. Treatment response calculated using using focal lesion number, MRI bone marrow pattern and functional parameters including SUVmax, ADC and fat fraction parameters, assessed by PET/CT and PET/MRI at baseline and at 4-6 weeks following completion of induction chemotherapy 3. Response/non-response to treatment assessed using clinical biomarkers and clinical review following completion of induction chemotherapy and following bone marrow transplant, including 100-day post-transplant bone marrow biopsy, where performed. Patients will be followed up by the clinical haematology team as per standard clinical practice.	—

Measure

Time frame

1. Myeloma bone disease detection, calculated using using focal lesion number, MRI bone marrow pattern and functional parameters including SUVmax, ADC and fat fraction parameters, assessed by PET/CT and PET/MRI at baseline and at 4-6 weeks following completion of induction chemotherapy 2. Treatment response calculated using using focal lesion number, MRI bone marrow pattern and functional parameters including SUVmax, ADC and fat fraction parameters, assessed by PET/CT and PET/MRI at baseline and at 4-6 weeks following completion of induction chemotherapy 3. Response/non-response to treatment assessed using clinical biomarkers and clinical review following completion of induction chemotherapy and following bone marrow transplant, including 100-day post-transplant bone marrow biopsy, where performed. Patients will be followed up by the clinical haematology team as per standard clinical practice.

—

Countries

England, United Kingdom

Contacts

Public ContactChimtom Nwaosu

chimtom.nwaosu@gstt.nhs.uk+44 (0)7701234816

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026